EPHA3 and glioblastoma: This biosimilar antibody was used to determine the cell surface expression of EphA3 across multiple GBM lines (U251CL, U118, U87, and A172) and the DIPG cell lines (SU-DIPG36GL, SU-DIPG4, SU-DIPG13, SU-DIPG33) (figure 1D).